Preemption Summary Judgment Granted In Incretin-Mimetic Multidistrict Litigation

(November 10, 2015, 10:56 AM EST) -- SAN DIEGO — The California federal judge overseeing the incretin mimetic multidistrict litigation on Nov. 9 granted summary judgment to five makers or promoters of the diabetes drugs, finding clear evidence that the Food and Drug Administration would have rejected a new warning about the risk of pancreatic cancer from the drugs (In Re: Incretin-Based Therapies Products Liability Litigation, MDL Docket No. 2452, S.D. Calif.).

(Incretin mimetic opinion available. Document #28-151112-015Z.)

The summary judgment ruling applies to all cases in the MDL. As of Oct. 15,...
To view the full article, register now.